XXXX : prognostic significance and clinically relevant markers.

@entity1 @entity986 @entity5 @entity14361 @entity876 @entity281 @entity1800 @entity1799 @entity7906
The association of high-risk @entity1 @entity5 (TC) has been documented. Because @entity1 with @entity5 show better survival rates, modification of their treatment regimen is being considered. It is therefore crucial to find markers for the identification of @entity1 whose @entity5 are linked to @entity1800 . A cohort of 109 @entity1 with primary TC was screened for HPV DNA presence in the @entity5 tissues and HPV-specific antibodies in sera. Data regarding risk factors and clinical parameters were collected. Forty-five specimens were analyzed for the expression of viral E6 and E2-region mRNA, and the @entity986 and @entity876 protein expression status was assessed by immunohistochemistry. The overall prevalence of HPV DNA in TC tissues was 65.1%. Ninety-three percent of HR HPV DNA-positive samples expressed E6*I mRNA. E2-region mRNA expression was detected in 36% of positive samples, which implies that the virus is integrated in 64% of HPV DNA/RNA-positive @entity5 . @entity986 overexpression and the presence of antibodies specific to @entity1799 @entity7906 oncoproteins correlated well with HPV DNA and RNA presence. The disease-specific survival rate of @entity1 with @entity5 was significantly higher than that of HPV DNA-negative @entity1 . In addition to providing further evidence of the involvement of @entity281 in the etiopathogenesis of a proportion of TC cases, our study demonstrates that @entity986 immunostaining and anti- @entity7906 antibodies as surrogate markers of @entity14361 represent specific, sensitive and clinically accessible assays for the identification of TC @entity1 who have a considerably better prognosis.
